JP6867288B2 - リファマイシンの眼科用組成物およびその使用 - Google Patents

リファマイシンの眼科用組成物およびその使用 Download PDF

Info

Publication number
JP6867288B2
JP6867288B2 JP2017525516A JP2017525516A JP6867288B2 JP 6867288 B2 JP6867288 B2 JP 6867288B2 JP 2017525516 A JP2017525516 A JP 2017525516A JP 2017525516 A JP2017525516 A JP 2017525516A JP 6867288 B2 JP6867288 B2 JP 6867288B2
Authority
JP
Japan
Prior art keywords
weight
composition
rifampicin
pharmaceutically acceptable
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017525516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525758A (ja
JP2017525758A5 (enExample
Inventor
セリザワ，ヒロアキ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AMD THERAPEUTICS LLC
Original Assignee
AMD THERAPEUTICS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AMD THERAPEUTICS LLC filed Critical AMD THERAPEUTICS LLC
Publication of JP2017525758A publication Critical patent/JP2017525758A/ja
Publication of JP2017525758A5 publication Critical patent/JP2017525758A5/ja
Application granted granted Critical
Publication of JP6867288B2 publication Critical patent/JP6867288B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017525516A 2014-07-21 2015-07-20 リファマイシンの眼科用組成物およびその使用 Active JP6867288B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462027189P 2014-07-21 2014-07-21
US62/027,189 2014-07-21
US201562136222P 2015-03-20 2015-03-20
US62/136,222 2015-03-20
US201562174884P 2015-06-12 2015-06-12
US62/174,884 2015-06-12
PCT/US2015/041196 WO2016014437A1 (en) 2014-07-21 2015-07-20 Ophthalmic compositions of rifamycins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021001928A Division JP2021073209A (ja) 2014-07-21 2021-01-08 リファマイシンの眼科用組成物およびその使用

Publications (3)

Publication Number Publication Date
JP2017525758A JP2017525758A (ja) 2017-09-07
JP2017525758A5 JP2017525758A5 (enExample) 2018-08-30
JP6867288B2 true JP6867288B2 (ja) 2021-04-28

Family

ID=55163601

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017525516A Active JP6867288B2 (ja) 2014-07-21 2015-07-20 リファマイシンの眼科用組成物およびその使用
JP2021001928A Withdrawn JP2021073209A (ja) 2014-07-21 2021-01-08 リファマイシンの眼科用組成物およびその使用
JP2022111021A Withdrawn JP2022137176A (ja) 2014-07-21 2022-07-11 リファマイシンの眼科用組成物およびその使用
JP2024091997A Pending JP2024129025A (ja) 2014-07-21 2024-06-06 リファマイシンの眼科用組成物およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021001928A Withdrawn JP2021073209A (ja) 2014-07-21 2021-01-08 リファマイシンの眼科用組成物およびその使用
JP2022111021A Withdrawn JP2022137176A (ja) 2014-07-21 2022-07-11 リファマイシンの眼科用組成物およびその使用
JP2024091997A Pending JP2024129025A (ja) 2014-07-21 2024-06-06 リファマイシンの眼科用組成物およびその使用

Country Status (3)

Country Link
US (4) US20170202850A1 (enExample)
JP (4) JP6867288B2 (enExample)
WO (1) WO2016014437A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170202850A1 (en) * 2014-07-21 2017-07-20 Hiroaki Serizawa Ophthalmic compositions of rifamycins and uses thereof
CN106176593A (zh) * 2016-08-29 2016-12-07 安徽艾珂尔制药有限公司 一种滴眼用利福平制剂及其制备方法
MX2022003075A (es) * 2019-09-12 2022-07-11 BioVersys AG Métodos de tratamiento, usos y composiciones de rifabutina.
WO2021058656A1 (en) * 2019-09-24 2021-04-01 Bausch Health Ireland Limited Rifaximin liquid formulations
US20240058329A1 (en) * 2020-12-21 2024-02-22 Bnc Korea Co., Ltd. Ophthalmic composition of rifamycin, and use thereof
WO2023234423A1 (en) * 2022-06-03 2023-12-07 Amd Therapeutics Llc Rifamycin ophthalmic composition and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR208F (enExample) 1964-07-31
IT1056272B (it) 1975-06-13 1982-01-30 Archifar Ind Chim Trentino Prodotti derivati dalle amine aromatiche
US4604384A (en) * 1982-06-24 1986-08-05 Smith Robert A Pharmaceutical gel composition
CN1020252C (zh) 1987-12-26 1993-04-14 沈阳市红旗制药厂 利福平眼膏的制备方法
CA1304363C (en) 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
CN1088800A (zh) * 1993-01-02 1994-07-06 鞍山钢铁公司 一种治疗皮肤烫烧伤的外敷中药膏及其制备方法
US6015803A (en) * 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US20030096735A1 (en) * 2001-09-28 2003-05-22 D'amato Robert J. Use of melanin for inhibition of angiogenesis and macular degeneration
HUP0001769A2 (hu) * 2000-05-04 2002-01-28 dr. Kahán Ilona Molnárné Lakrofil készítmény alkalmazása gyógyászati hatóanyag-tartalmú szemcseppekben
JP4393098B2 (ja) * 2002-06-21 2010-01-06 独立行政法人科学技術振興機構 アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法
CN1511526A (zh) 2002-12-30 2004-07-14 天津合益达生物医学技术有限公司 利福昔明软膏
WO2008109397A2 (en) * 2007-03-02 2008-09-12 Saint Simeon Lda Novel ophthalmic compositions containing human recombinant lysozyme and use thereof for treating eye conditions and as contact lens solutions
CA2716110A1 (en) * 2008-02-21 2009-08-27 Tim Mcnamara Ophthalmic nsaids as adjuvants
KR101906177B1 (ko) * 2008-12-10 2018-10-10 시플라 리미티드 리팍시민 복합체
CA2810598A1 (en) 2010-09-13 2012-03-22 Cipla Limited Pharmaceutical composition
US20170202850A1 (en) * 2014-07-21 2017-07-20 Hiroaki Serizawa Ophthalmic compositions of rifamycins and uses thereof

Also Published As

Publication number Publication date
US20240156830A1 (en) 2024-05-16
JP2017525758A (ja) 2017-09-07
US20210369726A1 (en) 2021-12-02
JP2022137176A (ja) 2022-09-21
US20170202850A1 (en) 2017-07-20
WO2016014437A1 (en) 2016-01-28
JP2021073209A (ja) 2021-05-13
US20190255065A1 (en) 2019-08-22
JP2024129025A (ja) 2024-09-26
US11850213B2 (en) 2023-12-26

Similar Documents

Publication Publication Date Title
US20240156830A1 (en) Ophthalmic compositions of rifamycins and uses thereof
JP5659388B2 (ja) 医学及び獣医眼科の使用のための医薬組成物
EP2175858B1 (en) Pharmaceutical compositions and methods of treating dry eye disorders
JP6017956B2 (ja) ボレート−ポリオール複合体を含む水性薬学的組成物
JP6800939B2 (ja) 視機能を改善するためのフェントラミンの連日眼科投与のための方法および組成物
JP6994061B2 (ja) ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
JP2014532641A (ja) レバミピドと涙液保持作用を有する薬剤からなる前眼部疾患治療剤
US20090306128A1 (en) Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
WO2022138639A1 (ja) リファマイシンの眼科用組成物およびその使用
CN116897046A (zh) 含有熊去氧胆酸或其盐的水性医药组合物
JP7118579B1 (ja) エピナスチン又はその塩を含有する水性組成物
WO2024135837A1 (ja) 組織移行性及び防腐効力を向上させるエピナスチン含有水性組成物
KR20230021613A (ko) 안구건조증 치료를 위한 레코플라본 함유 점안 조성물 및 이의 제조방법
CA2929965C (en) Method and composition for treating glaucoma
JP2022527621A (ja) 麻酔薬組成物及び眼を麻酔する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180717

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210108

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210108

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210125

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210125

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210318

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210323

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210408

R150 Certificate of patent or registration of utility model

Ref document number: 6867288

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250